Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15,380Revenue (TTM) $M1,201Net Margin (%)-14.5Altman Z-Score7.4
Enterprise Value $M15,328EPS (TTM) $-1.0Operating Margin %-17.4Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-19.1Higher ROA y-yY
Price/Book5.510-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsY
Price/Sales12.65-y EBITDA Growth Rate %182Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-4.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-6.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M175ROIC % (ttm)-6.4Gross Margin Increase y-yN

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BMRN is held by these investors:



BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAFFI ROBERTEVP, Technical Operations 2017-09-28Sell18,415$92.43-5.06view
Ajer Jeffrey RobertEVP, Chief Commercial Officer 2017-09-22Sell3,521$95-7.63view
LAWLIS V BRYANDirector 2017-09-15Sell3,750$91.26-3.85view
FUCHS HENRY JPresident, Worldwide R&D 2017-09-15Sell15,000$90.5-3.04view
Davis George EricEVP, General Counsel 2017-06-23Sell9,844$96.6-9.16view
Mueller BrianSVP, Corporate Controller 2017-06-22Sell2,671$100-12.25view
FUCHS HENRY JPresident, Worldwide R&D 2017-06-19Sell15,000$90-2.5view
LAWLIS V BRYANDirector 2017-06-16Sell3,750$90-2.5view
Ajer Jeffrey RobertEVP, Chief Commercial Officer 2017-06-07Sell1,004$89.61-2.08view
BIENAIME JEAN JACQUESCEO 2017-06-05Sell10,000$90.13-2.64view

Press Releases about BMRN :

Quarterly/Annual Reports about BMRN:

News about BMRN:

Articles On GuruFocus.com
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New Yor Oct 18 2017 
BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell Oct 16 2017 
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New Y Oct 11 2017 
BioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, Octob Oct 10 2017 
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors Oct 03 2017 
FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics Li Sep 14 2017 
BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome Sep 06 2017 
BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn E Sep 05 2017 
FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Des Aug 29 2017 
BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Sub Aug 23 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK